| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 11 | 2021 | 137 | 2.780 |
Why?
|
| Prostatic Neoplasms | 8 | 2025 | 1068 | 2.450 |
Why?
|
| Leptin | 9 | 2021 | 118 | 2.280 |
Why?
|
| Carcinoma, Hepatocellular | 10 | 2023 | 158 | 2.230 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2020 | 25 | 2.190 |
Why?
|
| Adenocarcinoma | 9 | 2010 | 287 | 1.950 |
Why?
|
| Exons | 5 | 2025 | 91 | 1.840 |
Why?
|
| Fibronectins | 4 | 2020 | 69 | 1.830 |
Why?
|
| Liver Neoplasms | 9 | 2023 | 211 | 1.780 |
Why?
|
| Cell Line, Tumor | 26 | 2025 | 2598 | 1.480 |
Why?
|
| Up-Regulation | 6 | 2025 | 534 | 1.420 |
Why?
|
| Gallic Acid | 2 | 2022 | 11 | 1.380 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2025 | 933 | 1.360 |
Why?
|
| Apoptosis | 16 | 2020 | 1541 | 1.320 |
Why?
|
| Liver Neoplasms, Experimental | 3 | 2015 | 21 | 1.310 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2021 | 297 | 1.300 |
Why?
|
| Cell Proliferation | 14 | 2025 | 1420 | 1.260 |
Why?
|
| Barrett Esophagus | 5 | 2009 | 29 | 1.170 |
Why?
|
| Cyclooxygenase 2 | 9 | 2019 | 106 | 1.090 |
Why?
|
| Gastrins | 4 | 2009 | 9 | 1.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 502 | 0.970 |
Why?
|
| Hepatitis B | 3 | 2023 | 41 | 0.960 |
Why?
|
| Neuroendocrine Tumors | 1 | 2025 | 11 | 0.920 |
Why?
|
| Humans | 51 | 2025 | 42163 | 0.920 |
Why?
|
| Neoplasms | 5 | 2023 | 1341 | 0.910 |
Why?
|
| Signal Transduction | 10 | 2025 | 2111 | 0.910 |
Why?
|
| Adiponectin | 4 | 2013 | 59 | 0.870 |
Why?
|
| Hepatocyte Growth Factor | 3 | 2013 | 19 | 0.850 |
Why?
|
| Pancreatic Neoplasms | 4 | 2020 | 206 | 0.830 |
Why?
|
| Janus Kinase 2 | 6 | 2013 | 33 | 0.800 |
Why?
|
| GTP Phosphohydrolases | 2 | 2021 | 33 | 0.780 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2021 | 11 | 0.730 |
Why?
|
| New York City | 5 | 2023 | 283 | 0.690 |
Why?
|
| Glioblastoma | 1 | 2021 | 69 | 0.680 |
Why?
|
| Plasmacytoma | 1 | 2020 | 11 | 0.670 |
Why?
|
| Cell Movement | 7 | 2025 | 640 | 0.670 |
Why?
|
| Oncogene Protein v-akt | 2 | 2012 | 20 | 0.670 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 25 | 0.660 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 290 | 0.660 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 129 | 0.650 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 55 | 0.640 |
Why?
|
| Receptors, Oxytocin | 1 | 2019 | 9 | 0.640 |
Why?
|
| Gene Dosage | 1 | 2019 | 75 | 0.630 |
Why?
|
| Oxytocin | 1 | 2019 | 24 | 0.630 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 233 | 0.620 |
Why?
|
| Cell Division | 4 | 2008 | 314 | 0.610 |
Why?
|
| Male | 17 | 2025 | 22779 | 0.590 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 228 | 0.580 |
Why?
|
| Enzyme Activation | 9 | 2021 | 462 | 0.580 |
Why?
|
| Cell Separation | 2 | 2015 | 94 | 0.570 |
Why?
|
| Mice, Inbred BALB C | 6 | 2019 | 686 | 0.550 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2006 | 82 | 0.540 |
Why?
|
| Colonic Neoplasms | 4 | 2011 | 223 | 0.540 |
Why?
|
| Vaccination | 1 | 2019 | 332 | 0.540 |
Why?
|
| Emigrants and Immigrants | 1 | 2019 | 156 | 0.540 |
Why?
|
| RNA, Small Interfering | 7 | 2020 | 436 | 0.540 |
Why?
|
| Diet | 2 | 2022 | 810 | 0.540 |
Why?
|
| Transcription Factors | 1 | 2021 | 722 | 0.510 |
Why?
|
| Epithelial Cells | 1 | 2019 | 426 | 0.500 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 144 | 0.470 |
Why?
|
| Translocation, Genetic | 3 | 2020 | 40 | 0.450 |
Why?
|
| Mice | 10 | 2020 | 6490 | 0.440 |
Why?
|
| Animals | 16 | 2020 | 16695 | 0.430 |
Why?
|
| MicroRNAs | 2 | 2017 | 501 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 9 | 0.410 |
Why?
|
| Sulfonamides | 7 | 2011 | 88 | 0.400 |
Why?
|
| NF-kappa B | 4 | 2008 | 355 | 0.390 |
Why?
|
| Disease Models, Animal | 3 | 2015 | 1554 | 0.380 |
Why?
|
| STAT3 Transcription Factor | 3 | 2013 | 97 | 0.360 |
Why?
|
| Prognosis | 4 | 2020 | 850 | 0.350 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2019 | 649 | 0.350 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 274 | 0.330 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2010 | 11 | 0.330 |
Why?
|
| Epoprostenol | 1 | 2010 | 28 | 0.330 |
Why?
|
| Pyrazoles | 5 | 2010 | 93 | 0.330 |
Why?
|
| Prostate | 2 | 2023 | 152 | 0.320 |
Why?
|
| Cadherins | 3 | 2019 | 102 | 0.320 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2007 | 43 | 0.300 |
Why?
|
| Obesity | 2 | 2008 | 1131 | 0.300 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2019 | 165 | 0.290 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2011 | 98 | 0.290 |
Why?
|
| Intestinal Mucosa | 2 | 2007 | 131 | 0.290 |
Why?
|
| Dinoprostone | 4 | 2012 | 69 | 0.280 |
Why?
|
| Receptors, Adiponectin | 1 | 2008 | 5 | 0.280 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2008 | 18 | 0.280 |
Why?
|
| RNA, Messenger | 4 | 2019 | 1265 | 0.270 |
Why?
|
| Cell Line | 3 | 2019 | 1416 | 0.270 |
Why?
|
| Phosphorylation | 5 | 2011 | 973 | 0.270 |
Why?
|
| Acids | 1 | 2007 | 19 | 0.270 |
Why?
|
| Gastrointestinal Agents | 1 | 2007 | 6 | 0.270 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 90 | 0.260 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 100 | 0.260 |
Why?
|
| Endothelial Cells | 1 | 2010 | 324 | 0.260 |
Why?
|
| Phosphotransferases | 1 | 2006 | 35 | 0.250 |
Why?
|
| Disease Progression | 3 | 2019 | 661 | 0.250 |
Why?
|
| Colitis | 1 | 2007 | 69 | 0.250 |
Why?
|
| Gastrointestinal Diseases | 1 | 2006 | 51 | 0.240 |
Why?
|
| Female | 8 | 2023 | 24018 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2019 | 255 | 0.240 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1221 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 201 | 0.230 |
Why?
|
| Adipose Tissue | 1 | 2006 | 180 | 0.230 |
Why?
|
| Aged | 4 | 2022 | 7982 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 284 | 0.220 |
Why?
|
| Gene Knockdown Techniques | 3 | 2020 | 188 | 0.220 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 522 | 0.200 |
Why?
|
| Gene Expression | 2 | 2019 | 692 | 0.200 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2009 | 34 | 0.200 |
Why?
|
| Cell Differentiation | 2 | 2020 | 633 | 0.200 |
Why?
|
| Hepatitis B, Chronic | 1 | 2023 | 16 | 0.200 |
Why?
|
| HT29 Cells | 3 | 2007 | 60 | 0.190 |
Why?
|
| Cause of Death | 1 | 2023 | 183 | 0.190 |
Why?
|
| Cytokines | 1 | 2006 | 661 | 0.190 |
Why?
|
| Databases, Genetic | 2 | 2019 | 103 | 0.180 |
Why?
|
| tRNA Methyltransferases | 1 | 2021 | 1 | 0.180 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 5 | 0.180 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 506 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2021 | 21 | 0.180 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 22 | 0.180 |
Why?
|
| Vimentin | 2 | 2012 | 38 | 0.180 |
Why?
|
| Prostate-Specific Antigen | 1 | 2023 | 145 | 0.180 |
Why?
|
| Methyltransferases | 1 | 2021 | 66 | 0.170 |
Why?
|
| Vegetables | 1 | 2022 | 145 | 0.170 |
Why?
|
| Risk Factors | 2 | 2019 | 3942 | 0.170 |
Why?
|
| Fruit | 1 | 2022 | 178 | 0.170 |
Why?
|
| Epidermal Growth Factor | 2 | 2012 | 69 | 0.160 |
Why?
|
| Africa | 1 | 2019 | 81 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 116 | 0.160 |
Why?
|
| Endostatins | 1 | 2019 | 5 | 0.160 |
Why?
|
| Mollusk Venoms | 1 | 2019 | 23 | 0.160 |
Why?
|
| RNA | 1 | 2021 | 266 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2019 | 13 | 0.150 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 32 | 0.150 |
Why?
|
| Middle Aged | 3 | 2019 | 11819 | 0.150 |
Why?
|
| Survival Rate | 1 | 2019 | 353 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2019 | 143 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 41 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2023 | 467 | 0.140 |
Why?
|
| Feeding Behavior | 1 | 2022 | 461 | 0.140 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 512 | 0.140 |
Why?
|
| Liver | 2 | 2019 | 503 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 638 | 0.140 |
Why?
|
| Hospitalization | 1 | 2021 | 482 | 0.140 |
Why?
|
| Mutation | 2 | 2019 | 1169 | 0.140 |
Why?
|
| RNA Interference | 2 | 2009 | 246 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2021 | 2485 | 0.130 |
Why?
|
| Tyrphostins | 2 | 2008 | 15 | 0.130 |
Why?
|
| Cell Survival | 3 | 2013 | 934 | 0.130 |
Why?
|
| Receptors, Leptin | 2 | 2007 | 14 | 0.130 |
Why?
|
| Cell Membrane | 1 | 2019 | 400 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2019 | 733 | 0.130 |
Why?
|
| Logistic Models | 1 | 2019 | 1001 | 0.130 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 330 | 0.130 |
Why?
|
| Peptides | 1 | 2019 | 357 | 0.130 |
Why?
|
| Transcriptional Activation | 2 | 2008 | 173 | 0.130 |
Why?
|
| Interleukin-8 | 2 | 2007 | 74 | 0.120 |
Why?
|
| Age Factors | 1 | 2019 | 1139 | 0.120 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 146 | 0.120 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2006 | 105 | 0.120 |
Why?
|
| Mass Screening | 1 | 2019 | 531 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2006 | 139 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 680 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2013 | 7 | 0.100 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2013 | 33 | 0.100 |
Why?
|
| Mesoderm | 1 | 2013 | 73 | 0.100 |
Why?
|
| Models, Biological | 2 | 2013 | 711 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 18 | 0.100 |
Why?
|
| Niacinamide | 1 | 2012 | 16 | 0.100 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 2803 | 0.100 |
Why?
|
| Cell Transplantation | 1 | 2012 | 4 | 0.090 |
Why?
|
| Matrix Metalloproteinases | 2 | 2013 | 49 | 0.090 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2012 | 7 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2012 | 35 | 0.090 |
Why?
|
| Albumins | 1 | 2012 | 32 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1058 | 0.090 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2012 | 44 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 34 | 0.090 |
Why?
|
| Models, Animal | 1 | 2011 | 149 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 3077 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 97 | 0.090 |
Why?
|
| Base Sequence | 1 | 2013 | 997 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 860 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 573 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 152 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 534 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2011 | 237 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 959 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1559 | 0.080 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 7 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 456 | 0.080 |
Why?
|
| Imidazoles | 2 | 2011 | 138 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2013 | 393 | 0.080 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2009 | 4 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 884 | 0.080 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2008 | 8 | 0.070 |
Why?
|
| Young Adult | 1 | 2019 | 4936 | 0.070 |
Why?
|
| RNA Stability | 1 | 2008 | 28 | 0.070 |
Why?
|
| Adolescent | 1 | 2019 | 5950 | 0.070 |
Why?
|
| Pravastatin | 1 | 2008 | 6 | 0.070 |
Why?
|
| Polyisoprenyl Phosphates | 1 | 2008 | 8 | 0.070 |
Why?
|
| Lovastatin | 1 | 2008 | 10 | 0.070 |
Why?
|
| Mevalonic Acid | 1 | 2008 | 9 | 0.070 |
Why?
|
| Okadaic Acid | 1 | 2008 | 14 | 0.070 |
Why?
|
| Nitrobenzenes | 1 | 2008 | 19 | 0.070 |
Why?
|
| Simvastatin | 1 | 2008 | 29 | 0.070 |
Why?
|
| Sesquiterpenes | 1 | 2008 | 38 | 0.070 |
Why?
|
| Immunoblotting | 1 | 2008 | 181 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 37 | 0.070 |
Why?
|
| Multienzyme Complexes | 1 | 2008 | 69 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2008 | 100 | 0.070 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2008 | 64 | 0.070 |
Why?
|
| Protein Isoforms | 1 | 2008 | 139 | 0.070 |
Why?
|
| Caspase 3 | 1 | 2008 | 226 | 0.070 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2007 | 20 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 30 | 0.070 |
Why?
|
| Dextran Sulfate | 1 | 2007 | 17 | 0.070 |
Why?
|
| Glycoproteins | 1 | 2008 | 127 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2008 | 130 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2008 | 112 | 0.060 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2006 | 3 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2008 | 574 | 0.060 |
Why?
|
| Maleimides | 1 | 2006 | 12 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2006 | 14 | 0.060 |
Why?
|
| Adult | 2 | 2019 | 13458 | 0.060 |
Why?
|
| Anthracenes | 1 | 2006 | 15 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 39 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2006 | 31 | 0.060 |
Why?
|
| Sulfones | 1 | 2006 | 47 | 0.060 |
Why?
|
| Isoquinolines | 1 | 2006 | 50 | 0.060 |
Why?
|
| Nitriles | 1 | 2006 | 78 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 457 | 0.060 |
Why?
|
| Morpholines | 1 | 2006 | 73 | 0.060 |
Why?
|
| Tyrosine | 1 | 2006 | 119 | 0.060 |
Why?
|
| Chromones | 1 | 2006 | 53 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2006 | 189 | 0.060 |
Why?
|
| Cell Count | 1 | 2005 | 140 | 0.060 |
Why?
|
| Flavonoids | 1 | 2006 | 94 | 0.060 |
Why?
|
| Pyridines | 1 | 2006 | 134 | 0.060 |
Why?
|
| Minority Groups | 2 | 2023 | 663 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2005 | 169 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 136 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2006 | 95 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1112 | 0.060 |
Why?
|
| Research Design | 1 | 2007 | 370 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 339 | 0.060 |
Why?
|
| Down-Regulation | 2 | 2019 | 452 | 0.060 |
Why?
|
| Indoles | 1 | 2006 | 178 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2006 | 199 | 0.050 |
Why?
|
| Hepatitis B virus | 1 | 2023 | 18 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2007 | 1617 | 0.050 |
Why?
|
| Mentors | 1 | 2023 | 143 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2005 | 548 | 0.050 |
Why?
|
| Rats | 1 | 2008 | 3701 | 0.040 |
Why?
|
| Gamma Rays | 1 | 2020 | 27 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 62 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2019 | 74 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 120 | 0.040 |
Why?
|
| New Jersey | 1 | 2017 | 15 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2017 | 43 | 0.030 |
Why?
|
| Vietnam | 1 | 2017 | 61 | 0.030 |
Why?
|
| Hawaii | 1 | 2023 | 2004 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 239 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 233 | 0.030 |
Why?
|
| Genomics | 1 | 2016 | 289 | 0.030 |
Why?
|
| Antibodies, Immobilized | 1 | 2013 | 8 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 84 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 77 | 0.020 |
Why?
|
| raf Kinases | 1 | 2012 | 7 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2012 | 48 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 54 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2012 | 158 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 246 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2011 | 27 | 0.020 |
Why?
|
| Naphthoquinones | 1 | 2011 | 41 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2011 | 79 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 154 | 0.020 |
Why?
|
| Rodentia | 1 | 2009 | 47 | 0.020 |
Why?
|
| Mitochondria | 1 | 2012 | 516 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 83 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 170 | 0.020 |
Why?
|
| United States | 1 | 2016 | 5072 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 979 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 928 | 0.010 |
Why?
|